SCHEMBL6769049

SCHEMBL6769049

Cc1c(O)c(C(C)(C)C)cc2c1CC(C)(C)O2

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.39
ALDH1A1 P00352 3/20 0.39
CA2 P00918 3/20 0.39
POLB P06746 1/20 0.39
TYR P14679 1/20 0.39
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
GALR3 O60755 1/20 0.37
HTT P42858 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
CA1 P00915 2/20 0.36
CYP2C19 P33261 4/20 0.36
CYP2C9 P11712 3/20 0.36
CYP1A2 P05177 2/20 0.36
MAPT P10636 2/20 0.35
KDM4E B2RXH2 1/20 0.35
HIF1A Q16665 2/20 0.34
TP53 P04637 1/20 0.34
HSPA5 P11021 1/20 0.33
HPN P05981 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1972110 0.85 CYP3A4 (0.37) SMN1; SMN2ALDH1A1CA2POLBTYR
SCHEMBL5476912 0.84 SMN1; SMN2 (0.37) SMN1; SMN2ALDH1A1CA2POLBTYR
SCHEMBL6768799 0.81 SMN1; SMN2 (0.34) SMN1; SMN2ALDH1A1CA2POLBTYR
SCHEMBL6130778 0.80 ALDH1A1 (0.38) SMN1; SMN2ALDH1A1CA2MEN1KMT2A
SCHEMBL6768175 0.80 KDM4E (0.38) SMN1; SMN2ALDH1A1CA2POLBTYR
SCHEMBL6768875 0.76 MAPT (0.33) ALDH1A1MEN1KMT2AHTTMAPT
SCHEMBL9028187 0.75 CA1 (0.36) ALDH1A1CA2CA1MAPTKDM4E
SCHEMBL4462428 0.74 ALDH1A1 (0.35) SMN1; SMN2ALDH1A1CA2POLBTYR
SCHEMBL9047877 0.73 TP53 (0.39) SMN1; SMN2ALDH1A1CA2POLBTYR
SCHEMBL9028190 0.73 MAOA (0.36) SMN1; SMN2ALDH1A1MEN1KMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6686389-B2 KIDNEY DISEASE, ORGAN TRANSPLANT CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2004-02-03 US disclosed
US-20020156296-A1 2,3-dihydrobenzofuran derivatives CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2002-10-24 US disclosed
US-6403639-B1 POTENT CYTOPROTECTIVE AGENT WHICH INHIBITS LIPID-PEROXIDATION FOR PREVENTION AND TREATMENT OF VARIOUS RENAL DISEASES CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2002-06-11 US disclosed
EP-0995437-A1 2,3-DIHYDROBENZOFURAN DERIVATIVES CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2000-04-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020156296-A1 2,3-dihydrobenzofuran derivatives CBR1, CYP2F1, NDUFAF2 SMN1; SMN2 1237/4885ALDH1A1 7/4885CA2 1997/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.